ArticleBone marrow transplantation2011
Toll-like receptor 9, NOD2 and IL23R gene polymorphisms influenced outcome in AML patients transplanted from HLA-identical sibling donors.
Article in Bone marrow transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Pooled it
- A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.Blood advances · 2018Trial
- Toll-Like Receptor Polymorphisms Influence Graft-Versus-Host Disease and Infection Risk After Single-Unit Cord Blood Transplantation for Adults.European journal of haematology · 2026Article
- Investigation Role of Toll-like Receptor-9 Gene and miR-155 Expression Levels in Acute Myeloid Leukemia via Quantitative Real-Time PCR.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Innate immune-inflammatory signaling milieu in myeloid leukemia and aging-associated clonal hematopoiesis pathologies.Frontiers in immunology · 2025Review
- Extracorporeal photopheresis reduces the T cell stimulatory capacity of human primary blood conventional dendritic cells type 1.Frontiers in immunology · 2025Article
- Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice.Molecular therapy. Nucleic acids · 2024Article
- Lower overall survival in male patients with advanced disease undergoing allogeneic hematopoietic stem cell transplantation is associated withHaematologica · 2024Article
- Association of TLR4 Rs4986791 Polymorphism and TLR9 Haplotypes with Acute Myeloid Leukemia Susceptibility: A Case-Control Study of Adult Patients.Journal of personalized medicine · 2022Article
- Genetic variants associated with inflammatory bowel disease and gut graft-versus-host disease.Blood advances · 2021Article
- CD markers polymorphisms as prognostic biomarkers in hematological malignancies.Oncology reviews · 2020Article
- Toll-like receptor 9 negatively related to clinical outcome of AML patients.Journal of the Egyptian National Cancer Institute · 2020Article
- Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications.Frontiers in immunology · 2020Review
- Genetic polymorphism related to monocyte-macrophage function is associated with graft-versus-host disease.Scientific reports · 2017Article
- Article
- Sensing danger: toll-like receptors and outcome in allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2017Review
- Role of Toll-Like Receptor Signaling in the Pathogenesis of Graft-versus-Host Diseases.International journal of molecular sciences · 2016Review
- Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives.Frontiers in immunology · 2016Review
- Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.Mucosal immunology · 2015Review
- Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?Current hematologic malignancy reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the influence of gene polymorphisms of TLR9 (T1237C; T1486C), IL23R (A1142G), and NOD2 SNP8 (R702W), SNP12 (G908R) and SNP13 (1007fs) on outcome of hematopoietic SCT in a homogenous group of 142 AML patients after non-T-cell-depleted myeloablative transplantation from HLA-identical sibling donors. In our retrospective study, we found that TLR9 gene variant at 1486 influenced transplant outcome. Estimated 5-year OS in patients with the CC gene variant of TLR9 was 70.2% compared with 44.8% (P<0.027) in patients with TC/TT of TLR9 gene. No significant influences on 5-year OS were found for gene polymorphisms of NOD2 or IL23R (A1142G) in this study group. The 5-year treatment-related mortality was lowest in patients with CC gene variant of TLR9 (7.8 vs 23.1%; NS). Acute GVHD grade III-IV was higher in patients with NOD2 gene variants (28 vs 12.8%; P=0.065). In contrast, patients transplanted from donors with the gene variant of IL23R had no occurrence of severe acute GVHD grade III-IV (0 vs 18.4%; P<0.048). However, multivariate analysis confirmed the influence of NOD2 gene variants on the occurrence of acute GVHD grade II-IV after transplant. These results suggest that the gene variants of TLR9, NOD2 and Il23R had influence on the outcome of transplant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.